131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

This study tests a radioactive drug called 131I-TLX-101 (iobenguane I-131) in people with newly diagnosed glioblastoma — an aggressive brain cancer. The drug is designed to deliver targeted radiation directly to brain tumor cells. This is a Phase 2 study evaluating how well the treatment works. **You may be eligible if...** - You have been newly diagnosed with glioblastoma (a type of aggressive brain tumor) - You have completed or are completing standard initial treatment (surgery and/or radiation with temozolomide chemotherapy) - You are 18 years or older - Your tumor shows certain features that the drug can target - Your general health is good enough to participate (adequate organ function) **You may NOT be eligible if...** - Your cancer has already progressed or recurred - You have received prior treatment with this type of radioactive drug - You have severe organ problems (kidney, liver, bone marrow) - You are pregnant or breastfeeding - You are unable to follow radiation safety precautions after dosing Talk to your doctor to see if this trial is right for you.